drugset / Trial / NCT00867152

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

NCT00867152

Phase 1 Completed 17 enrolled ViiV Healthcare Shionogi · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

A Phase I, open label, randomized, three period, one-way, two cohort, adaptive crossover study to evaluate the effect of darunavir/ritonavir plus etravirine and lopinavir/ritonavir plus etravirine on GSK1349572 pharmacokinetics in healthy adult subjects

Timeline

Start
2009-04
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg
Subject Dolutegravir Other / unclassified 20 mg
Subject Dolutegravir Other / unclassified 50 mg
Subject Lopinavir Other / unclassified 400 mg
Background Etravirine Small molecule 200 mg
Background Ritonavir Other / unclassified 100 mg

Indications

No indication recorded.